

Montana Healthcare Programs Drug Utilization Review Board Agenda
Hosted by Mountain Pacific Quality Health
October 25, 2023
1-4 PM
Virtual Call Only

Register in advance for this meeting:

<https://mpqhf.zoom.us/meeting/register/tZMuc-6hqTMjGdKsFHGc8iGrpBErS1SmdkPU>

1. Introductions

2. Public Comment- 15 minutes.

All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via <https://forms.office.com/g/EkPyKbJYTv> by **noon** the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person and is subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to PDL@mt.gov at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information.

3. Meeting Minutes

4. Department Update

5. Atypical antipsychotics- this agenda item will be postponed until our next meeting when our psychiatrist will be available for the discussion.

6. PA Criteria updates:

- Suggested Change to Current Criteria.
 - Ampyra® (dalfampridine) ER-criteria removal
 - Zinplava® (bezlotoxumab)- criteria removal due to new guidelines in treatment of CDI
- Age Extensions and Language Updates
 - Fasentra®-PA and PAD consolidation
 - Trikafta®
 - Savella®
 - Cibinqo®
- New Indications
 - Ingrezza®

- Rinvoq®
- Leqvio®
- Linzess®
- Qulipta®

7. New Drugs

- Austedo XR®
- Zavzpret®
- Vowst®